BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33672813)

  • 1. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.
    Huang D; Sun L; Huang L; Chen Y
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H; Fang J; Maeda H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
    Danhier F; Danhier P; De Saedeleer CJ; Fruytier AC; Schleich N; des Rieux A; Sonveaux P; Gallez B; Préat V
    Int J Pharm; 2015 Feb; 479(2):399-407. PubMed ID: 25578367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
    Greish K
    Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
    Fang J; Sawa T; Maeda H
    Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
    Islam R; Maeda H; Fang J
    Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model.
    Wang D; Fu J; Shi Y; Peng D; Yuan L; He B; Dai W; Zhang H; Wang X; Tian J; Zhang Q
    J Control Release; 2016 Sep; 238():186-196. PubMed ID: 27422610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Captopril improves tumor nanomedicine delivery by increasing tumor blood perfusion and enlarging endothelial gaps in tumor blood vessels.
    Zhang B; Jiang T; Tuo Y; Jin K; Luo Z; Shi W; Mei H; Hu Y; Pang Z; Jiang X
    Cancer Lett; 2017 Dec; 410():12-19. PubMed ID: 28939029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
    Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advocation and advancements of EPR effect theory in drug delivery science: A commentary.
    Hashida M
    J Control Release; 2022 Jun; 346():355-357. PubMed ID: 35483640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
    Maeda H; Tsukigawa K; Fang J
    Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
    Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
    Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
    Maeda H
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect.
    Ejigah V; Owoseni O; Bataille-Backer P; Ogundipe OD; Fisusi FA; Adesina SK
    Polymers (Basel); 2022 Jun; 14(13):. PubMed ID: 35808648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.
    Kinoshita R; Ishima Y; Ikeda M; Kragh-Hansen U; Fang J; Nakamura H; Chuang VT; Tanaka R; Maeda H; Kodama A; Watanabe H; Maeda H; Otagiri M; Maruyama T
    J Control Release; 2015 Nov; 217():1-9. PubMed ID: 26302904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
    Fang J; Islam W; Maeda H
    Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Factors Determining the Enhanced Permeability and Retention Effect in Subcutaneous Xenografts.
    Bolkestein M; de Blois E; Koelewijn SJ; Eggermont AM; Grosveld F; de Jong M; Koning GA
    J Nucl Med; 2016 Apr; 57(4):601-7. PubMed ID: 26719375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.